ABSTRACT
Objective To evaluate the outcomes and safety of ESD in colorectal SMTs. Methods Between January 2011 and January 2017, we performed ESD on 68 consecutive colorectal SMTs in 67 patients. We evaluated the clinical outcomes of all said cases. Results The most common type of the 68 colorectal SMTs was neuroendocrine tumor (42/68, 61.8%), followed by lipoma (20/68, 29.4%). Most of neuroendocrine tumors (41/42) were located in rectum, and most of lipomas (18/20) were located in colon. Among the 46 tumors which were evaluated by endoscopic ultrasonography (EUS) before ESD,38 tumors (82.6%) were located in the submucosal layer, and 31 tumors (67.4%) were hypoecho. Our overall endoscopic en bloc resection rate was 100.0%, and our R0 resection rate was 94.1% respectively. Our perforation rate of ESD was 6.0%, delayed bleeding rate 1.5%. None of the patients need surgical intervention because of complication. Follow-up rate was 95.5%, no recurrence or metastasis was observed during the median follow-up period 33 months (range 3~75 months). Conclusion EUS is conductive to the diagnosis of colorectal SMTs before ESD. ESD is a safe and effective treatment for colorectal SMTs.